文献速递中医内科中药与中成药合理使用

中药注射剂联合奥司他韦治疗流感的系统评价与网状Meta分析

Traditional Chinese Medicine Injections Combined With Oseltamivir for Influenza: Systematic Review and Network Meta-Analysis.
PubMed 文献 · Front Pharmacol · 2022-07-22

结果显示部分联合方案在退热时间、咳嗽消失时间和有效率上可能优于单用奥司他韦,但证据质量低至极低,安全性无显著差异,总体疗效与安全性结论不确定。

要点

  • 喜炎平联合奥司他韦在有效率上可能优于单用奥司他韦(OR=5.9,95%CrI 3.1–11),证据质量极低。
  • 痰热清联合奥司他韦在咳嗽消失时间上可能最优(MD=-1.9,95%CrI -2.8至-1),证据质量低。
  • 炎琥宁联合奥司他韦在退热时间上可能优于单用奥司他韦(MD=-1.7,95%CrI -2.5至-0.88),证据质量低。

核心结论

  • 中药注射剂联合奥司他韦仅部分改善流感症状,总体疗效与安全性结论不确定,证据质量低至极低。
  • 联合治疗与单用奥司他韦在安全性方面无显著差异,但安全性仍不确定,应谨慎考虑中药注射剂用于流感。

研究设计与样本

  • 比较4种中药注射剂联合奥司他韦与奥司他韦,采用贝叶斯随机方法进行网状Meta分析,并做敏感性分析、Meta回归及Egger's和Begg's检验。

主要发现

  • 退热时间:炎琥宁联合奥司他韦优于单用奥司他韦(MD=-1.7,95%CrI -2.5至-0.88;SUCRA=0.89;证据质量低)。
  • 咳嗽消失时间:痰热清联合奥司他韦优于单用奥司他韦(MD=-1.9,95%CrI -2.8至-1;SUCRA=0.97;证据质量低)。
  • 有效率:喜炎平联合奥司他韦优于单用奥司他韦(OR=5.9,95%CrI 3.1至11;SUCRA=0.82;证据质量极低)。
  • 基于主要结局的联合SUCRA值,痰热清联合奥司他韦在咳嗽消失时间上可能更优,喜炎平和炎琥宁联合奥司他韦在退热时间上可能更优。
  • 各治疗之间安全性无显著差异。

关键数值与推荐

  • 退热时间MD=-1.7(95%CrI -2.5至-0.88),SUCRA=0.89,证据质量低(炎琥宁联合奥司他韦 vs 奥司他韦)。
  • 咳嗽消失时间MD=-1.9(95%CrI -2.8至-1),SUCRA=0.97,证据质量低(痰热清联合奥司他韦 vs 奥司他韦)。
  • 有效率OR=5.9(95%CrI 3.1至11),SUCRA=0.82,证据质量极低(喜炎平联合奥司他韦 vs 奥司他韦)。

临床怎么用

  • 在流感患者中,可考虑痰热清联合奥司他韦以缩短咳嗽消失时间,但需告知证据质量低。
  • 炎琥宁或喜炎平联合奥司他韦可能分别改善退热时间和有效率,但证据质量低至极低,应谨慎使用。
  • 中药注射剂联合奥司他韦的安全性尚未确定,临床决策需权衡获益与不确定性。

局限性

  • 纳入研究证据质量低至极低,总体疗效与安全性结论不确定。
  • 安全性仍不确定,中药注射剂治疗流感应谨慎考虑。
  • 需要更多高质量研究评估中药注射剂的疗效与安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: As a cause of respiratory tract infections in humans, influenza remains with high morbidity and mortality, with associated significant healthcare burden and increased financial burden. Traditional Chinese medicine injections (TCMIs) combined with oseltamivir (TCMIs + oseltamivir) are the representative therapeutic strategies for influenza, which is a compliant with clinical applications in China. The aim of this study was to describe the comparative efficacy and safety of TCMIs + oseltamivir in patients with influenza, based on the current evidence. Methods: PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure, Wanfang Data Knowledge Service Platform, VIP information resource integration service platform databases, and the Chinese biomedical literature service system were searched to find randomized controlled trials where TCMIs + oseltamivir are the representative therapeutic strategies for influenza, from inception until October 2021, without language restriction. Two investigators independently screened eligibility criteria, extracted data, and appraised the risk of bias with the same criteria. We conducted a network meta-analysis using the Bayesian random method for each outcome and performed the sensitivity analysis, meta-regression, and Egger's and Begg's tests for the reliability and robustness of our results. Results: Thirty-one trials including 2,893 participants proved eligible and reported on four TCMIs + oseltamivir versus oseltamivir. Network meta-analysis showed Yanhuning (YHN) +oseltamivir (MD = -1.7, 95% CrI: -2.5 to -0.88; SUCRA = 0.89; low certainty of evidence) in fever disappearance time, Tanreqing (TRQ) +oseltamivir (MD = -1.9, 95% CrI: -2.8 to -1; SUCRA = 0.97; low certainty of evidence) in cough disappearance time, and Xiyanping (XYP) +oseltamivir (OR = 5.9, 95% CrI: 3.1 to 11; SUCRA = 0.82; very low certainty of evidence) in the response rate to be more efficacious than oseltamivir alone with the best SUCRA. Based on the combined SUCRA value for primary outcomes, TRQ + oseltamivir is probably better in cough disappearance time, and XYP + oseltamivir and YHN + oseltamivir may be better in fever disappearance time than others. No significant difference in safety between the treatments. Conclusion: In patients with influenza, TCMIs + oseltamivir only partially improve flu symptoms. Overall therapeutic efficacy and safety are inconclusive, based on low to very low certainty of evidence. However, the safety remains uncertain, and TCMI treatments for influenza should be considered with caution. More high-quality studies examining the efficacy and safety of TCMIs are needed. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42021286994.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Peng Y, Chen Z, Li H, et al. Traditional Chinese Medicine Injections Combined With Oseltamivir for Influenza: Systematic Review and Network Meta-Analysis. Front Pharmacol. 2022. PMID: 35935865. doi:10.3389/fphar.2022.848770

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。